Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Llibre |
| Publicat: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |